Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function
Scott E. Collibee, Gustave Bergnes, Chih-Yuan Chuang, Luke Ashcraft, Jeffrey Gardina, Marc Garard, Chris R. Jamison, Kevin Lu, Pu‐Ping Lu, Alexander R. Muci, A. Romero, Ellen Valkevich, Wenyue Wang, Jeffrey M. Warrington, Bing Yao, Nickie Durham, James J. Hartman, Anna Marquez, Aaron C. Hinken, Julia Schaletzky, Donghong Xu, Darren T. Hwee, David J. Morgans, Fady I. Malik, B. Paul Morgan
Abstract
muscle activation potency compared to the first-generation FSTA, tirasemtiv. Reldesemtiv demonstrated increased muscle force generation in a phase 1 clinical trial and is currently being evaluated in clinical trials for the treatment of amyotrophic lateral sclerosis.
Topics & Concepts
Skeletal muscleTroponinChemistryTroponin IPotencyActivator (genetics)In vivoClinical trialMuscle contractionPharmacologyStimulationCardiac muscleInternal medicineCardiologyBiochemistryMedicineIn vitroBiotechnologyReceptorBiologyMyocardial infarctionCardiomyopathy and Myosin StudiesAmyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research